159979-96-1

Basic information

• Product Name: 1-(azidomethyl)-4-fluorobenzene(SALTDATA: FREE)
• Synonyms: 1-(azidomethyl)-4-fluorobenzene(SALTDATA: FREE);1-(Azidomethyl)-4-fluorobenzene solution;p-Fluorobenzyl azide solution;1-(Azidomethyl)-4-fluorobenzene solution ~0.5 M in dichloromethane, >=97.0% (HPLC)
• CAS NO: 159979-96-1
• Molecular Formula: C₇H₆FN₃
• Molecular Weight: 151.1410432
• Mol File: 159979-96-1.mol
• Article Data: 119

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• BRN: 8403292
• CAS DataBase Reference: 1-(azidomethyl)-4-fluorobenzene(SALTDATA: FREE)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(azidomethyl)-4-fluorobenzene(SALTDATA: FREE)(159979-96-1)
• EPA Substance Registry System: 1-(azidomethyl)-4-fluorobenzene(SALTDATA: FREE)(159979-96-1)

Safety Data

• Hazard Codes: Xn
• Statements: 40-48/20/21/22
• Safety Statements: 36/37
• RIDADR: UN 1593 6.1 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 159979-96-1(Hazardous Substances Data)

Usage

General Description

1-(azidomethyl)-4-fluorobenzene is a chemical compound with the molecular formula C7H6FN3. It is commonly used in organic synthesis and has potential applications in medicinal chemistry. 1-(azidomethyl)-4-fluorobenzene(SALTDATA: FREE) is known for its azido and fluoro substituents, which make it useful for various chemical reactions and modifications. It is important to handle this compound with care as azides are known to be highly explosive and should be handled by experienced chemists in a controlled environment. Overall, 1-(azidomethyl)-4-fluorobenzene has potential applications in the field of organic chemistry and drug discovery.

Upstream product

• 459-46-1 4-Fluorobenzyl bromide 
• 131948-17-9 2-formyl-N,N,N-trimethylbenzenaminium triflate 
• 134430-68-5 C₇H₇⁽¹⁸⁾FO 
• 134430-69-6 2-⁽¹⁸⁾fluorobenzyl bromide 
• 134430-71-0 C₇H₆⁽¹⁸⁾FI 
• 86656-36-2 2-<18F>fluorobenzaldehyde 
• 552-89-6 2-nitro-benzaldehyde 
• 459-56-3 4-fluorobenzylic alcohol 
• 140-75-0 para-fluorobenzylamine 
• 352-32-9 p-fluorotoluene 
• 456-22-4 4-Fluorobenzoic acid 
• 4648-54-8 trimethylsilylazide 
• 5651-83-2 3-methoxy-4-(prop-2-ynyloxy)benzaldehyde 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 119222-40-1 5-amino-1-[(4-fluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide 
• 659-41-6 4-fluorobenzenemethanamine hydrochloride 
• 1033391-37-5 7-{3-[1-(4-fluorobenzyl)-1H-[1,2,3]triazol-4-yl]phenylcarbamoyl}heptanoic acid methyl ester 
• 1033391-56-8 7-{3-[3-(4-fluorobenzyl)-3H-[1,2,3]triazol-4-yl]phenylcarbamoyl}heptanoic acid methyl ester 
• 1033391-22-8 7-{4-[1-(4-fluorobenzyl)-1H-[1,2,3]triazol-4-yl]phenylcarbamoyl}heptanoic acid methyl ester 
• 1033391-47-7 7-{4-[3-(4-fluorobenzyl)-3H-[1,2,3]triazol-4-yl]phenylcarbamoyl}heptanoic acid methyl ester 
• 1133862-82-4 2-[1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl]pyridine 
• 848950-93-6 1?(4?fluorobenzyl)?4?phenyl?1H?1,2,3?triazole 

Relevant articles and documents

Synthesis and biological activity of triazole-appended N,O-nucleosides

1,2,3-Triazole-appended N,O-nucleosides have been synthesized by an approach combining a 1,3-dipolar cycloaddition process and an alkyne-azide click chemistry reaction. Biological assays, performed on six tumor cell lines, revealed the antiproliferative a

Synthesis of (1,2,3‐triazol‐4‐yl)methyl phosphinates and (1,2,3‐Triazol‐4‐yl)methyl phosphates by copper‐catalyzed azide‐alkyne cycloaddition

An efficient and practical method was developed for the synthesis of new (1,2,3‐triazol‐4‐yl)methyl phosphinates and (1,2,3‐triazol‐4‐yl)methyl phosphates by the copper(I)‐catalyzed azide‐alkyne cycloaddition (CuAAC) of organic azides and prop‐2‐ynyl phos

Synthesis of novel triazolyl pyranochromen-2(1H)-ones and their antibacterial activity evaluation

A series of thirty-three novel triazolyl pyranochromen-2(1H)-one derivatives have been synthesized via Cu (I) catalysed Huisgen 1,3-dipolar cycloaddition reaction. All of the synthesized compounds have been fully characterized from their spectral data and evaluated for antibacterial activity against both gram-positive and gram-negative bacteria. The activity results revealed that amongst all the compounds screened, six compounds, i.e. 2-[4-(((7-ethyl-2,2,6-trimethyl-8-oxo-2,3,4,8-tetrahydropyrano[3,2-g]chromen-10-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl]acetic acid (41), 10-[(1-(1,3-dihydroxypropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy]-3-ethyl-4,8,8-trimethyl-7,8-dihydropyrano[3,2-g]chromen-2(6H)-one (44), 3-ethyl-4,8,8-trimethyl-10-[(1-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-triazol-4-yl)methoxy]-7,8-dihydropyrano[3,2-g]chromen-2(6H)-one (46), 2-[4-(((7-hexyl-2,2,6-trimethyl-8-oxo-2,3,4,8-tetrahydropyrano[3,2-g]chromen-10-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl]acetic acid (52), 10-[(1-(1,3-dihydroxypropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy]-3-hexyl-4,8,8-trimethyl-7,8-dihydropyrano[3,2-g]chromen-2(6H)-one (55) and 3-hexyl-4,8,8-trimethyl-10-[(1-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-triazol-4-yl)methoxy]-7,8-dihydropyrano[3,2-g]chromen-2(6H)-one (57), exhibited moderate activity against all the strains studied with zone of inhibition between 10 and 16?mm and MIC values in the range of 75–170?μg/mL as compared to the standard used. The information obtained from structure–activity relationship can be used to design and develop the next generation of compounds with higher antibacterial efficacy.

Synthesis and Cytotoxic Evaluation of Novel 1,2,3-Triazole-4-Linked (2E,6E)-2-Benzylidene-6-(4-nitrobenzylidene)cyclohexanones

This work describes the synthesis of novel 1,2,3-triazole-4-linked (2E,6E)-2-benzylidene-6-(4-nitrobenzylidene)cyclo-hexanones starting from cyclohexanone. 1-(Cyclohex-1-en-1-yl)piperidine, the enamine from cyclohexanone and piperidine, reacted with 4-nitrobenzaldehyde to obtain 2-(4-nitrobenzylidene)cyclohexanone. Condensation of the latter compound with (prop-2-yn-1-yloxy)benzaldehyde derivatives under acidic conditions gave (4-nitrobenzylidene)-[(prop-2-yn-1-yloxy)-benzylidene]cyclohexanones. Finally, 'click reaction' of these derivatives and various organic azides led to the title compounds. All compounds were examined by MTT assay for cytotoxic activity in one human breast cancer cell line, MDA-MB-231.

Discovery of triazolyl thalidomide derivatives as anti-fibrosis agents

Fibrosis with excessive accumulation of extracellular matrix (ECM) often causes progressive organ dysfunction and results in many inflammatory and metabolic diseases, including systemic sclerosis, pulmonary fibrosis, advanced liver disease and advanced kidney disease. The store-operated calcium entry (SOCE) pathway and the related signaling pathway were both found to be the important routes for fibrogenesis. Our aim in this study was to discover novel compounds to inhibit fibrogenesis. A number of triazolyl thalidomide derivatives were synthesized and evaluated for their anti-fibrosis activities. Compounds 7b-e, 8c-d, 10a-b and 10e inhibited intracellular Ca2+ activation and showed no cytotoxicity. Among them, 6-{4-[(3-(1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl}hexanoic acid (10e) with the most potent inhibitory effect was chosen for further examination. The results revealed that compound 10e, a SOCE inhibitor, reversed the migratory ability of TGF-β1-induced myofibroblasts, dedifferentiated myofibroblasts to fibroblasts due to cytoskeleton remodeling, and restrained myofibroblast activation by targeting Orai1 and TGF-β1/SMAD2/3 signaling pathways. The in silico study indicated that compound 10e, with the appropriate lipophilic carbon chain and carboxylic acid, showed a good drug-likeness model score. Conclusively, the SOCE inhibitor, compound 10e, is used as a promising lead compound for the development of a new treatment for fibrosis. This journal is

Synthesis, Docking, and Biological activities of novel Metacetamol embedded [1,2,3]-triazole derivatives

ERα controls the breast tissue development and progression of breast cancer. In our search for novel compounds to target Estrogen Receptor Alpha Ligand-Binding Domain, we identified “N-(3-((1H-1,2,3-triazol-4-yl)methoxy)phenyl)acetamide” derivatives as lead compounds. The Docking studies indicated good docking score for Metacetamol derivatives when docked into the 1XP6. A series of metacetamol derivatives have been synthesized, characterized and evaluated for cytotoxicity, anti bacterial and anti oxidant activities. Among the tested twelve hybrid compounds, “7a, 7g, 7h and 7i” derivatives showed promising cytotoxicity with IC50 value of 50 value of 30 μM, whereas Compounds “7a, 7b, 7c, 7d, 7g, 7j, 7k and 7l” showed moderate anti bacterial activity with the MIC value of 300 μM.